RAMBUS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RAMBUS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $101.89M | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $99.13M | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $94.72M | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $97.35M | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $97.56M | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $89.86M | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $76.50M | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $72.68M | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $76.77M | Feb 17, 2017 |
| FY2016 | Sep 30, 2015 | $73.78M | Feb 17, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $563.22M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $446.52M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $357.70M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $347.21M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $257.91M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $48.46M | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | $41.65M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $45.57M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $49.89M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $47.16M | Mar 29, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.46M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $179.82M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $333.90M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | ($14.31M) | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $18.33M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | ($12.06M) | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | ($12.74M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($9.14M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($6.54M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($6.88M) | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $260.22M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $183.01M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $153.64M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $76.94M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $24.28M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | ($11.00M) | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | ($12.50M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($11.09M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($9.46M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($10.60M) | Mar 29, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.71M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $162.88M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $156.83M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $158.77M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $135.68M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $139.84M | Feb 24, 2023 |
| FY2020 | Sep 30, 2020 | $33.73M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $34.69M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $36.66M | Mar 29, 2021 |
| FY2021 | Dec 31, 2019 | $156.82M | Feb 28, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.29M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $104.09M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $108.15M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $106.72M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $91.06M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $86.44M | Feb 24, 2023 |
| FY2020 | Sep 30, 2020 | $20.18M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $21.72M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $23.31M | Mar 29, 2021 |
| FY2021 | Dec 31, 2019 | $100.55M | Feb 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $360.02M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $230.60M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $195.79M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $230.39M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $209.22M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $185.46M | Feb 24, 2023 |
| FY2020 | Sep 30, 2020 | $143.39M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $99.27M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $37.26M | Mar 29, 2021 |
| FY2021 | Dec 31, 2019 | $128.54M | Feb 28, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.84M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $30.70M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $23.24M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $17.48M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $13.79M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $29.73M | Feb 24, 2023 |
| FY2020 | Sep 30, 2020 | $20.80M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $12.78M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $1.95M | Mar 29, 2021 |
| FY2021 | Dec 31, 2019 | $6.47M | Feb 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.34B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $1.26B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.01B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.23B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.25B | Feb 28, 2022 |
| FY2020 | Sep 30, 2020 | $1.32B | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $1.32B | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $1.33B | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $1.34B | Mar 29, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.12M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $222.44M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $220.13M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $233.30M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $370.25M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $338.70M | Feb 28, 2022 |
| FY2020 | Sep 30, 2020 | $350.72M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $351.41M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $353.79M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $368.07M | Mar 29, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.12B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $1.04B | Feb 18, 2026 |
| FY2025 | Dec 31, 2022 | $779.30M | Feb 18, 2026 |
| FY2024 | Dec 31, 2021 | $862.40M | Feb 24, 2025 |
| FY2023 | Dec 31, 2020 | $912.71M | Feb 23, 2024 |
| FY2020 | Sep 30, 2020 | $965.83M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $972.73M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $971.60M | Mar 29, 2021 |
| FY2022 | Dec 31, 2019 | $975.37M | Feb 24, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $286.81M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $286.81M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $286.81M | Feb 24, 2025 |
| FY2024 | Dec 31, 2022 | $292.04M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $278.81M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $183.22M | Feb 24, 2023 |
| FY2020 | Sep 30, 2020 | $183.22M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $183.22M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $183.47M | Mar 29, 2021 |
| FY2021 | Dec 31, 2019 | $183.47M | Feb 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.80M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | ($153.66M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | ($285.53M) | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | ($513.26M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | ($435.23M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($357.75M) | Feb 28, 2022 |
| FY2020 | Sep 30, 2020 | ($314.21M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($301.47M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($292.33M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($285.79M) | Mar 29, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.82M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $99.77M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $94.77M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $125.34M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $107.89M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $128.97M | Feb 24, 2023 |
| FY2020 | Sep 30, 2020 | $89.48M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $103.28M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $175.45M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $102.18M | Mar 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | (1) | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 22, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | (1) | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 22, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 107.78M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 106.84M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 107.85M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | 107.61M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 109.29M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 111.70M | Feb 28, 2022 |
| FY2020 | Sep 30, 2020 | 113.92M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | 113.74M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | 113.28M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | 112.13M | Mar 29, 2021 |